Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
Publication Artículo científico (JournalArticle)

Superinfection during treatment of nosocomial infections with tigecycline

  • García-Cabrera, Emilio
  • Jiménez-Mejías, Manuel E.
  • Gil-Navarro, María Victoria
  • Gómez-Gómez, M J
  • Ortiz-Leyba, C
  • Cordero, Elisa
  • Pachón, J
We performed a retrospective and observational study of 51 patients treated with tigecycline, as the treatment for nosocomial infections due to multidrug-resistant microorganisms, to evaluate the superinfection rate and their etiologies. Superinfections were diagnosed in 12 (23.5%) patients (seven due to Pseudomonas aeruginosa, 13.7%) and one patient had P. aeruginosa colonization. Five patients with superinfection died (41.6%), three due to superinfections and two to underlying diseases. The superinfection rate observed during tigecycline treatment is higher than that previously reported. Pseudomonas aeruginosa is the most frequent agent, being the cause of 58.5% of all superinfections., This study was supported by the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008, Instituto de Salud Carlos III-FEDER, Ministerio de Ciencia e Innovación)., Yes
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
Publication Artículo científico (JournalArticle)

Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment.

  • Garnacho-Montero, José
  • García-Cabrera, Emilio
  • Diaz-Martín, Ana
  • Lepe, José Antonio
  • Iraurgi-Arcarazo, Patricia
  • Jiménez-Alvarez, Rocio
  • Revuelto-Rey, Jaume
  • Aznar, Javier
We set out to determine the factors influencing mortality in 125 adult patients with bacteraemic pneumococcal community-acquired pneumonia (CAP), assessing the impact on outcomes of early adequate therapy in particular. Presumed prognostic factors with p < 0.1 in the unadjusted model were subjected to multivariate Cox regression analysis, with in-hospital and 90-day mortalities as the dependent variables. A time period of >4 h from admission to start of adequate antibiotic treatment (adjusted hazard ratio (aHR) 2.62, 95% confidence interval (CI) 1.06-6.45; p =0.037) and severe sepsis or septic shock (aHR 5.06, 95% CI 1.63-15.71; p = 0.005) were independently associated with in-hospital mortality. Variables associated with 90-day mortality were Charlson comorbidity index (aHR 1.17, 95% CI 1.02-1.34; p = 0.018), severe sepsis or septic shock (aHR 3.03, 95% CI 1.22-7.51; p = 0.016) and delay of adequate antibiotic therapy >4 h (aHR 2.21, 95% CI 1.01-4.86; p = 0.048). The use of combination therapy was not included in these models but was a protective factor for delayed adequate therapy (aHR 0.53, 95% CI 0.29-0.95; p = 0.033). Administration of adequate antimicrobial therapy within 4 h of arrival is a critical determinant of survival in patients with bacteraemic pneumococcal CAP., This study was supported by Consejería de Salud de la Junta de Andalucía. Exp. Num. 0185 (2006), and Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008)., Yes
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal

  • Villar, Macarena
  • Cano, María E.
  • Gato, Eva
  • Garnacho-Montero, José
  • Cisneros, José Miguel
  • Ruiz de Alegría-Puig, Carlos
  • Fernández-Cuenca, Felipe
  • Martínez-Martínez, Luis
  • Vila, Jordi
  • Pascual, Álvaro
  • Tomás, María
  • Bou, Germán
  • Rodríguez-Baño, Jesús
Observational study, [Abstract] Acinetobacter baumannii is one of the most important antibiotic-resistant nosocomial bacteria. We investigated changes in the clinical and molecular epidemiology of A. baumannii over a 10-year period. We compared the data from 2 prospective multicenter cohort studies in Spain, one performed in 2000 (183 patients) and one in 2010 (246 patients), which included consecutive patients infected or colonized by A. baumannii. Molecular typing was performed by repetitive extragenic palindromic polymerase chain reaction (REP-PCR), pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST). The incidence density of A. baumannii colonization or infection increased significantly from 0.14 in 2000 to 0.52 in 2010 in medical services (p < 0.001). The number of non-nosocomial health care-associated cases increased from 1.2% to 14.2%, respectively (p < 0.001). Previous exposure to carbapenems increased in 2010 (16.9% in 2000 vs 27.3% in 2010, p = 0.03). The drugs most frequently used for definitive treatment of patients with infections were carbapenems in 2000 (45%) and colistin in 2010 (50.3%). There was molecular-typing evidence of an increase in the frequency of A. baumannii acquisition in non-intensive care unit wards in 2010 (7.6% in 2000 vs 19.2% in 2010, p = 0.01). By MSLT, the ST2 clonal group predominated and increased in 2010. This epidemic clonal group was more frequently resistant to imipenem and was associated with an increased risk of sepsis, although not with severe sepsis or mortality. Some significant changes were noted in the epidemiology of A. baumannii, which is increasingly affecting patients admitted to conventional wards and is also the cause of non-nosocomial health care-associated infections. Epidemic clones seem to combine antimicrobial resistance and the ability to spread, while maintaining their clinical virulence., The study was funded by the Ministerio de Ciencia e Innovaci on, Instituto de Salud Carlos III, cofinanced by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008), and FIS (PI 10/00056 and PI 11/02046).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Actividad de 18 agentes antimicrobianos frente a aislados clínicos de Acinetobacter baumannii: segundo estudio nacional multicéntrico (proyecto GEIH-REIPI-Ab 2010), In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010

  • Fernández-Cuenca, Felipe
  • Tomás, María
  • Caballero-Moyano, Francisco-Javier
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Vila, Jordi
  • Pachón, Jerónimo
  • Cisneros, José Miguel
  • Rodríguez-Baño, Jesús
  • Pascual, Álvaro
Multicenter study, [Resumen] Objetivos. Determinar las tasas de resistencia antimicrobiana en Acinetobacter baumannii (A. baumannii) (proyecto GEIH-REIPI-Ab 2010) en España y compararlas con las obtenidas en el primer estudio realizado en 2000 (proyecto GEIH-Ab 2000). Métodos. Se incluyen 446 aislados de A. baumannii obtenidos en 43 hospitales españoles entre febrero y marzo de 2010. La identificación de especie se realizó mediante ARDRA y MALDI-TOF. Se evaluaron 18 antimicrobianos mediante microdilución en caldo (normativa del Clinical and Laboratory Standards Institute [CLSI]). Se aplicaron los puntos de corte establecidos por el CLSI, excepto para doripenem, rifampicina y sulbactam, en los que se utilizaron los puntos de corte establecidos por la Societé Française de Microbiologie (SFM), y tigeciclina (puntos de corte establecidos por el European Committee on Antimicrobial Susceptibility Testing [EUCAST]). Resultados. Los porcentajes de aislados resistentes (se incluyeron también los de sensibilidad intermedia) fueron: > 94% (ceftacidima, piperacilina y ciprofloxacino), 82-86% (carbapenémicos y tetraciclina), 60-70% (tobramicina, sulbactam, gentamicina y doxiciclina), 49% (amicacina), 30% (minociclina, rifampicina), 24% (tigeciclina) y 3% (colistina). Estos aislados fueron, en comparación con los del primer estudio, más resistentes (p < 0,01) a ceftacidima (99 vs. 83%), carbapenémicos (82-86 vs. 43-48%), sulbactam (65 vs. 53%) y colistina (3 vs. 0%), pero más sensibles a los aminoglucósidos (particularmente gentamicina: 70 vs. 96% de aislados resistentes), tetraciclina (83 vs. 91%) y rifampicina (30 vs. 51%). Conclusión. Hay una elevada prevalencia de A. baumannii resistente a antimicrobianos, particularmente a los carbapenémicos. Se ha producido un incremento en la resistencia a los carbapenémicos, ceftacidima y sulbactam mientras que para los aminoglucósidos, tetraciclina y rifampicina las resistencias han disminuido. Colistina continúa siendo el antimicrobiano con mayor actividad., [Abstract] Objetivos. Determinar las tasas de resistencia antimicrobiana en Acinetobacter baumannii (A. baumannii) (proyecto GEIH-REIPI-Ab 2010) en España y compararlas con las obtenidas en el primer estudio realizado en 2000 (proyecto GEIH-Ab 2000). Métodos. Se incluyen 446 aislados de A. baumannii obtenidos en 43 hospitales españoles entre febrero y marzo de 2010. La identificación de especie se realizó mediante ARDRA y MALDI-TOF. Se evaluaron 18 antimicrobianos mediante microdilución en caldo (normativa del Clinical and Laboratory Standards Institute [CLSI]). Se aplicaron los puntos de corte establecidos por el CLSI, excepto para doripenem, rifampicina y sulbactam, en los que se utilizaron los puntos de corte establecidos por la Societé Française de Microbiologie (SFM), y tigeciclina (puntos de corte establecidos por el European Committee on Antimicrobial Susceptibility Testing [EUCAST]). Resultados. Los porcentajes de aislados resistentes (se incluyeron también los de sensibilidad intermedia) fueron: > 94% (ceftacidima, piperacilina y ciprofloxacino), 82-86% (carbapenémicos y tetraciclina), 60-70% (tobramicina, sulbactam, gentamicina y doxiciclina), 49% (amicacina), 30% (minociclina, rifampicina), 24% (tigeciclina) y 3% (colistina). Estos aislados fueron, en comparación con los del primer estudio, más resistentes (p < 0,01) a ceftacidima (99 vs. 83%), carbapenémicos (82-86 vs. 43-48%), sulbactam (65 vs. 53%) y colistina (3 vs. 0%), pero más sensibles a los aminoglucósidos (particularmente gentamicina: 70 vs. 96% de aislados resistentes), tetraciclina (83 vs. 91%) y rifampicina (30 vs. 51%). Conclusión. Hay una elevada prevalencia de A. baumannii resistente a antimicrobianos, particularmente a los carbapenémicos. Se ha producido un incremento en la resistencia a los carbapenémicos, ceftacidima y sulbactam mientras que para los aminoglucósidos, tetraciclina y rifampicina las resistencias han disminuido. Colistina continúa siendo el antimicrobiano con mayor actividad., Financiado por el Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, cofinanciada por el Fondo Europeo de Desarrollo Regional «Una manera de hacer Europa», FEDER, Red Espanola de ˜ Investigación en Patología Infecciosa (REIPI RD06/0008).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems

  • Papp-Wallace, Krisztina M.
  • Mallo Cancela, Susana
  • Bethel, Christopher R.
  • Taracila, Magdalena A.
  • Hujer, Andrea M.
  • Viña Fernández, Anabel María
  • Gatta, Julian A.
  • Smith, Kerri M.
  • Xu, Yan
  • Page, Malcolm G.P.
  • Desarbre, Eric
  • Bou, Germán
  • Bonomo, Robert
[Abstract] Objectives: Class C β-lactamases are prevalent among Enterobacteriaceae; however, these enzymes are resistant to inactivation by commercially available β-lactamase inhibitors. In order to find novel scaffolds to inhibit class C β-lactamases, the comparative efficacy of monocyclic β-lactam antibiotics (aztreonam and the siderophore monosulfactam BAL30072), the bridged monobactam β-lactamase inhibitor BAL29880, and carbapenems (imipenem, meropenem, doripenem and ertapenem) were tested in kinetic assays against FOX-4, a plasmid-mediated class C β-lactamase (pmAmpC). Methods: The FOX-4 β-lactamase was purified. Steady-state kinetics, electrospray ionization mass spectrometry (ESI-MS) and ultraviolet difference (UVD) spectroscopy were conducted using the β-lactam scaffolds described. Results: The K(i) values for the monocyclic β-lactams against FOX-4 β-lactamase were 0.04 ± 0.01 μM (aztreonam) and 0.66 ± 0.03 μM (BAL30072), and the Ki value for the bridged monobactam BAL29880 was 8.9 ± 0.5 μM. For carbapenems, the Ki values ranged from 0.27 ± 0.05 μM (ertapenem) to 2.3 ± 0.3 μM (imipenem). ESI-MS demonstrated the formation of stable covalent adducts when the monocyclic β-lactams and carbapenems were reacted with FOX-4 β-lactamase. UVD spectroscopy suggested the appearance of different chromophoric intermediates. Conclusions: Monocyclic β-lactam and carbapenem antibiotics are effective mechanism-based inhibitors of FOX-4 β-lactamase, a clinically important pmAmpC, and provide stimulus for the development of new inhibitors to inactivate plasmidic and chromosomal class C β-lactamases., G. B. was funded by the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III-FEDER, Spanish Network for Research in Infectious Diseases (REIPI RD06/0008). This work was also funded by FIS PI12/00552, PS09/00687 and PS07/90 from Xunta de Galicia. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01 AI100560 and R01 AI063517 to R. A. B.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain

  • Espinal, Paula
  • Maciá, María Dolores
  • Roca, Ignasi
  • Gato, Eva
  • Ruiz de Gopegui, Enrique
  • Fernández-Cuenca, Felipe
  • Oliver, Antonio
  • Rodríguez-Baño, Jesús
  • Bou, Germán
  • Tomás, María
  • Vila, Jordi
Case report, [Abstract] A carbapenem-resistant Acinetobacter baumannii clinical isolate belonging to European clone II and sequence type 2 was recovered from a patient in the Son Espases hospital in Mallorca, Spain. Genetic analysis showed the presence of the bla(OXA-23) gene in association with the widely disseminated transposon Tn2006. This is the first reported identification of A. baumannii carrying bla(OXA-23) in Spain., This study was supported by the Spanish Ministry of Health (FIS PI10/00056) and by the Instituto de Salud Carlos III-FEDER, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008). This work was also supported by funding from the European Community (TROCAR contract HEALTH-F3-2008-223031). M. Tomás was financially supported by the Miguel Servet Program (CHU a Coruña and ISCIII).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Prevention Strategies for Cytomegalovirus Disease and Long-Term Outcomes in the High-Risk Transplant Patient (D+/R-): Experience from the RESITRA-REIPI Cohort

  • Meije, Yolanda
  • Fortún, Jesús
  • Len, Óscar
  • Aguado, José María
  • Moreno, Asunción V.
  • Cisneros, José Miguel
  • Gurgui, Mercé
  • Carratalá, Jordi A.
  • Muñoz-García, Patricia E.
  • Montejo, Miguel
  • Blanes, Marino
  • Bou, Germán
  • Beato Pérez, José Luis
  • Torre-Cisneros, Julián
  • Ramos-Martínez, Antonio S.D.
  • Pahissa, Alberto
  • Gavaldá, Joan
Multicenter study, [Abstract] Background: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. Methods: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. Results: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R-. The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. Conclusions: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation., This manuscript was supported by the Spanish Ministry of Health and Consumer Affairs, Instituto de Salud Carlos III, Spanish Network for research on Infection in Transplantation (grant G03/075), and Spanish Network for Research on Infectious Diseases (grant RD06/0008). Dr Y. Meije held a “Río Hortega” grant from ISCIII (Instituto de Salud Carlos III) and Fundación Hospital Ramón y Cajal.